Watarida S, Shiraishi S, Sugita T, Katsuyama K, Nakajima Y, Yamamoto R, Yamamoto Y, Imura M, Hirokawa R, Mori A
Second Department of Surgery, Shiga University of Medical Science, Seta Tsukinowa, Otsu, Shiga 520-2192, Japan.
Ann Thorac Cardiovasc Surg. 2000 Apr;6(2):106-9.
Docarpamine is a dopamine prodrug which has been selected from a large number of dopamine derivatives in order to develop an orally effective dopamine. The pharmacokinetics after oral administration of docarpamine have not yet been studied in children undergoing open heart surgery. This study examined the effects of docarpamine on hemodynamics and evaluated its safety in 11 children undergoing open heart surgery for congenital heart disease. This study began when the patientOs postoperative condition was stabilized by continuous dopamine infusion into the vein at a rate of 5 micro g/kg/min. The patients were administered 40 mg/kg of docarpamine every 8 hours, and hemodynamics were measured every 4 hours for 16 hours after the initial docarpamine administration. Immediately after the initial docarpamine administration, the dose of dopamine was reduced to 3 micro g/kg/min. Infusion of dopamine was stopped 8 hours after the initial docarpamine administration. Systemic systolic and diastolic blood pressure and heart rate showed no significant changes. Mean right atrial pressure decreased 4 hours after docarpamine administration. Mixed venous oxygen saturation and mean velocity of circumferential fiber shortening increased significantly after docarpamine administration. No significant changes were observed in urine volume. All patients could be weaned from dopamine within 8 hours. No changes were observed in ECG, and no arrhythmia-inducing action was noted. Our study indicates that 40 mg/kg oral doses of docarpamine produce plasma dopamine concentration equivalent to those of a 3 to 5 micro g/kg/min dopamine infusion. Our data suggest that docarpamine is a safe and effective drug for children who have undergone open heart surgery.
多卡巴胺是一种多巴胺前体药物,它是从大量多巴胺衍生物中筛选出来的,目的是开发一种口服有效的多巴胺。尚未对接受心脏直视手术的儿童口服多卡巴胺后的药代动力学进行研究。本研究检测了多卡巴胺对血流动力学的影响,并评估了其在11例接受先天性心脏病心脏直视手术儿童中的安全性。本研究在患者术后病情通过以5μg/kg/min的速率持续静脉输注多巴胺得以稳定后开始。患者每8小时服用40mg/kg的多卡巴胺,在首次服用多卡巴胺后的16小时内,每4小时测量一次血流动力学。在首次服用多卡巴胺后,立即将多巴胺的剂量降至3μg/kg/min。在首次服用多卡巴胺8小时后停止输注多巴胺。体循环收缩压和舒张压以及心率均无显著变化。服用多卡巴胺4小时后,平均右心房压降低。服用多卡巴胺后,混合静脉血氧饱和度和圆周纤维缩短平均速度显著增加。尿量未观察到显著变化。所有患者均可在8小时内停用多巴胺。心电图未观察到变化,也未发现有致心律失常作用。我们的研究表明,口服40mg/kg剂量的多卡巴胺产生的血浆多巴胺浓度与以3至5μg/kg/min的速率输注多巴胺时相当。我们的数据表明,多卡巴胺对于接受心脏直视手术的儿童是一种安全有效的药物。